Neoantigen Cancer Vaccine Market Size, Share, and Trends 2025 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology 

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Neoantigen Cancer Vaccine Market 

5.1. COVID-19 Landscape: Neoantigen Cancer Vaccine Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Neoantigen Cancer Vaccine Market, By Product Type

8.1. Neoantigen Cancer Vaccine Market, by Product Type

8.1.1. Personalized Neoantigen Vaccines

8.1.1.1. Market Revenue and Forecast

8.1.2. Off-the-Shelf Neoantigen Vaccines

8.1.2.1. Market Revenue and Forecast

Chapter 9. Global Neoantigen Cancer Vaccine Market, By Neoantigen Source

9.1. Neoantigen Cancer Vaccine Market, by Neoantigen Source

9.1.1. Tumour Mutations

9.1.1.1. Market Revenue and Forecast

9.1.2. Tumour-Associated Antigens

9.1.2.1. Market Revenue and Forecast

Chapter 10. Global Neoantigen Cancer Vaccine Market, By Administration Route 

10.1. Neoantigen Cancer Vaccine Market, by Administration Route

10.1.1. Intravenous

10.1.1.1. Market Revenue and Forecast

10.1.2. Intramuscular

10.1.2.1. Market Revenue and Forecast

10.1.3. Transdermal

10.1.3.1. Market Revenue and Forecast

10.1.4. Others

10.1.4.1. Market Revenue and Forecast

Chapter 11. Global Neoantigen Cancer Vaccine Market, By Technology Platform

11.1. Neoantigen Cancer Vaccine Market, by Technology Platform

11.1.1. mRNA-Based Vaccines

11.1.1.1. Market Revenue and Forecast

11.1.2. Peptide-Based Vaccines

11.1.2.1. Market Revenue and Forecast

11.1.3. Viral Vector-Based Vaccines

11.1.3.1. Market Revenue and Forecast

11.1.4. Others

11.1.4.1. Market Revenue and Forecast

Chapter 12. Global Neoantigen Cancer Vaccine Market, By Application

12.1. Neoantigen Cancer Vaccine Market, by Application

12.1.1. Melanoma

12.1.1.1. Market Revenue and Forecast

12.1.2. Non-Small Cell Lung Cancer (NSCLC)

12.1.2.1. Market Revenue and Forecast

12.1.3. Pancreatic Cancer

12.1.3.1. Market Revenue and Forecast

12.1.4. Others

12.1.4.1. Market Revenue and Forecast

Chapter 13. Global Neoantigen Cancer Vaccine Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Product Type

13.1.2. Market Revenue and Forecast, by Neoantigen Source

13.1.3. Market Revenue and Forecast, by Administration Route

13.1.4. Market Revenue and Forecast, by Technology Platform

13.1.5. Market Revenue and Forecast, by Application

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Product Type

13.1.6.2. Market Revenue and Forecast, by Neoantigen Source

13.1.6.3. Market Revenue and Forecast, by Administration Route

13.1.6.4. Market Revenue and Forecast, by Technology Platform

13.1.6.5. Market Revenue and Forecast, by Application  

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Product Type

13.1.7.2. Market Revenue and Forecast, by Neoantigen Source

13.1.7.3. Market Revenue and Forecast, by Administration Route

13.1.7.4. Market Revenue and Forecast, by Technology Platform

13.1.7.5. Market Revenue and Forecast, by Application

13.2. Europe

13.2.1. Market Revenue and Forecast, by Product Type

13.2.2. Market Revenue and Forecast, by Neoantigen Source

13.2.3. Market Revenue and Forecast, by Administration Route

13.2.4. Market Revenue and Forecast, by Technology Platform  

13.2.5. Market Revenue and Forecast, by Application  

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Product Type

13.2.6.2. Market Revenue and Forecast, by Neoantigen Source

13.2.6.3. Market Revenue and Forecast, by Administration Route

13.2.7. Market Revenue and Forecast, by Technology Platform  

13.2.8. Market Revenue and Forecast, by Application  

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Product Type

13.2.9.2. Market Revenue and Forecast, by Neoantigen Source

13.2.9.3. Market Revenue and Forecast, by Administration Route

13.2.10. Market Revenue and Forecast, by Technology Platform

13.2.11. Market Revenue and Forecast, by Application

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Product Type

13.2.12.2. Market Revenue and Forecast, by Neoantigen Source

13.2.12.3. Market Revenue and Forecast, by Administration Route

13.2.12.4. Market Revenue and Forecast, by Technology Platform

13.2.13. Market Revenue and Forecast, by Application

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Product Type

13.2.14.2. Market Revenue and Forecast, by Neoantigen Source

13.2.14.3. Market Revenue and Forecast, by Administration Route

13.2.14.4. Market Revenue and Forecast, by Technology Platform

13.2.15. Market Revenue and Forecast, by Application

13.3. APAC

13.3.1. Market Revenue and Forecast, by Product Type

13.3.2. Market Revenue and Forecast, by Neoantigen Source

13.3.3. Market Revenue and Forecast, by Administration Route

13.3.4. Market Revenue and Forecast, by Technology Platform

13.3.5. Market Revenue and Forecast, by Application

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Product Type

13.3.6.2. Market Revenue and Forecast, by Neoantigen Source

13.3.6.3. Market Revenue and Forecast, by Administration Route

13.3.6.4. Market Revenue and Forecast, by Technology Platform

13.3.7. Market Revenue and Forecast, by Application

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Product Type

13.3.8.2. Market Revenue and Forecast, by Neoantigen Source

13.3.8.3. Market Revenue and Forecast, by Administration Route

13.3.8.4. Market Revenue and Forecast, by Technology Platform

13.3.9. Market Revenue and Forecast, by Application

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Product Type

13.3.10.2. Market Revenue and Forecast, by Neoantigen Source

13.3.10.3. Market Revenue and Forecast, by Administration Route

13.3.10.4. Market Revenue and Forecast, by Technology Platform

13.3.10.5. Market Revenue and Forecast, by Application

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Product Type

13.3.11.2. Market Revenue and Forecast, by Neoantigen Source

13.3.11.3. Market Revenue and Forecast, by Administration Route

13.3.11.4. Market Revenue and Forecast, by Technology Platform

13.3.11.5. Market Revenue and Forecast, by Application

13.4. MEA

13.4.1. Market Revenue and Forecast, by Product Type

13.4.2. Market Revenue and Forecast, by Neoantigen Source

13.4.3. Market Revenue and Forecast, by Administration Route

13.4.4. Market Revenue and Forecast, by Technology Platform

13.4.5. Market Revenue and Forecast, by Application

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Product Type

13.4.6.2. Market Revenue and Forecast, by Neoantigen Source

13.4.6.3. Market Revenue and Forecast, by Administration Route

13.4.6.4. Market Revenue and Forecast, by Technology Platform

13.4.7. Market Revenue and Forecast, by Application

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Product Type

13.4.8.2. Market Revenue and Forecast, by Neoantigen Source

13.4.8.3. Market Revenue and Forecast, by Administration Route

13.4.8.4. Market Revenue and Forecast, by Technology Platform

13.4.9. Market Revenue and Forecast, by Application

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Product Type

13.4.10.2. Market Revenue and Forecast, by Neoantigen Source

13.4.10.3. Market Revenue and Forecast, by Administration Route

13.4.10.4. Market Revenue and Forecast, by Technology Platform

13.4.10.5. Market Revenue and Forecast, by Application

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Product Type

13.4.11.2. Market Revenue and Forecast, by Neoantigen Source

13.4.11.3. Market Revenue and Forecast, by Administration Route

13.4.11.4. Market Revenue and Forecast, by Technology Platform

13.4.11.5. Market Revenue and Forecast, by Application

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Product Type

13.5.2. Market Revenue and Forecast, by Neoantigen Source

13.5.3. Market Revenue and Forecast, by Administration Route

13.5.4. Market Revenue and Forecast, by Technology Platform

13.5.5. Market Revenue and Forecast, by Application

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Product Type

13.5.6.2. Market Revenue and Forecast, by Neoantigen Source

13.5.6.3. Market Revenue and Forecast, by Administration Route

13.5.6.4. Market Revenue and Forecast, by Technology Platform

13.5.7. Market Revenue and Forecast, by Application

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Product Type

13.5.8.2. Market Revenue and Forecast, by Neoantigen Source

13.5.8.3. Market Revenue and Forecast, by Administration Route

13.5.8.4. Market Revenue and Forecast, by Technology Platform

13.5.8.5. Market Revenue and Forecast, by Application

Chapter 14. Company Profiles

14.1. Poseida Therapeutics, Inc.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Precision BioSciences, Inc.

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Inovio Pharmaceuticals, Inc

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Axsome Therapeutics, Inc

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Advaxis, Inc.

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Agenus Inc

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Vaccibody AS

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Novogene Co., Ltd

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Moderna Inc

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. BioNTech SE

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms